Lensar (LNSR) Income from Continuing Operations (2019 - 2026)
Lensar's (LNSR) quarterly Income from Continuing Operations came in at 42000.0 in Q1 2026, up 99.81% year-on-year from 21019.95 in Q1 2025, and up 99.75% on a QoQ basis from 16507000.0 in Q4 2025.
Lensar (LNSR) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Lensar (LNSR) has 8 years of Income from Continuing Operations data on file, last reported at 42000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 99.81% year-over-year to 42000.0 in Q1 2026; TTM through Mar 2026 was 57981000.0, a 45.02% decrease from a year earlier, with the FY2025 full-year figure at 36167000.0, down 106.41% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 42000.0, up from 16507000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for LNSR reached as high as 42000.0 in Q1 2026 and fell as low as 22122000.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 9718529.41 across 5 years, with a median of 8158000.0 in 2024.
- Across the five-year window, Income from Continuing Operations plunged 539.88% in 2025 and surged 99.81% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 3271000.0 in 2022, then retreated by 3.64% to 3390000.0 in 2023, then tumbled by 140.65% to 8158000.0 in 2024, then plunged by 102.34% to 16507000.0 in 2025, then soared by 99.75% to 42000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 42000.0 in Q1 2026, 16507000.0 in Q4 2025, and 20585000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Lensar | 70.05 Mn | 72.73 Mn | 6.38 Mn | -42,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42,000.00 |
| Dec 31, 2025 | -16.51 Mn |
| Sep 30, 2025 | -20.59 Mn |
| Jun 30, 2025 | -20.85 Mn |
| Mar 31, 2025 | -22.12 Mn |
| Dec 31, 2024 | -8.16 Mn |
| Sep 30, 2024 | -3.22 Mn |
| Jun 30, 2024 | -6.48 Mn |
| Mar 31, 2024 | -7.27 Mn |
| Dec 31, 2023 | -3.39 Mn |
| Sep 30, 2023 | -7.26 Mn |
| Jun 30, 2023 | -4.08 Mn |
| Mar 31, 2023 | -9.54 Mn |
| Dec 31, 2022 | -3.27 Mn |
| Sep 30, 2022 | -10.27 Mn |
| Jun 30, 2022 | -11.14 Mn |
| Mar 31, 2022 | -11.03 Mn |
| Dec 31, 2021 | -4.43 Mn |
| Sep 30, 2021 | -11.57 Mn |
| Jun 30, 2021 | -9.78 Mn |